DK3520786T3 - Kombination af stoffer til anvendelse i regenerativ terapi til patienter med type 1 diabetes mellitus - Google Patents
Kombination af stoffer til anvendelse i regenerativ terapi til patienter med type 1 diabetes mellitus Download PDFInfo
- Publication number
- DK3520786T3 DK3520786T3 DK18182706.4T DK18182706T DK3520786T3 DK 3520786 T3 DK3520786 T3 DK 3520786T3 DK 18182706 T DK18182706 T DK 18182706T DK 3520786 T3 DK3520786 T3 DK 3520786T3
- Authority
- DK
- Denmark
- Prior art keywords
- patients
- substances
- combination
- type
- diabetes mellitus
- Prior art date
Links
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title 1
- 230000001172 regenerating effect Effects 0.000 title 1
- 239000000126 substance Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2018104548A RU2694527C1 (ru) | 2018-02-06 | 2018-02-06 | Комбинация для регенеративной терапии больных сахарным диабетом 1 типа |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3520786T3 true DK3520786T3 (da) | 2023-09-25 |
Family
ID=62909455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18182706.4T DK3520786T3 (da) | 2018-02-06 | 2018-07-10 | Kombination af stoffer til anvendelse i regenerativ terapi til patienter med type 1 diabetes mellitus |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11116768B2 (da) |
| EP (1) | EP3520786B1 (da) |
| DK (1) | DK3520786T3 (da) |
| ES (1) | ES2957268T3 (da) |
| FI (1) | FI3520786T3 (da) |
| HR (1) | HRP20231177T1 (da) |
| HU (1) | HUE062944T2 (da) |
| LT (1) | LT3520786T (da) |
| PL (1) | PL3520786T3 (da) |
| PT (1) | PT3520786T (da) |
| RS (1) | RS64638B1 (da) |
| RU (1) | RU2694527C1 (da) |
| SI (1) | SI3520786T1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023037160A2 (ru) * | 2021-09-10 | 2023-03-16 | Левикуре Лтд. | Набор и разовая дозированная форма для профилактики сахарного диабета 1 типа, их применение для профилактики сахарного диабета 1 типа. способ профилактики сахарного диабета 1 типа у здоровых людей из группы высокого риска |
| WO2023238126A1 (en) * | 2022-06-07 | 2023-12-14 | Levicure Ltd | Composition and method for use thereof for treatment and prevention of autoimmune and neurological disorders |
| WO2024052896A1 (en) * | 2022-09-05 | 2024-03-14 | Levicure Ltd. | Combination of therapeutic agents and method for use thereof for treatment and prevention of endocrine, autoimmune and neurological disorders |
| WO2024173747A1 (en) * | 2023-02-17 | 2024-08-22 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US20090042781A1 (en) | 2004-06-28 | 2009-02-12 | Novo Nordisk A/S | Methods for Treating Diabetes |
| CA2622579C (en) * | 2005-09-20 | 2013-12-31 | Novartis Ag | Use of a dpp-iv inhibitor to reduce hypoglycemic events |
| US9463174B2 (en) * | 2008-12-19 | 2016-10-11 | Qinghua Wang | Pharmaceutical composition for the treatment of type-1 diabetes |
| RU2601622C1 (ru) * | 2015-10-29 | 2016-11-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации, (ВолгГМУ) | Средство, обладающее эндотелиопротекторным действием в условиях экспериментального сахарного диабета и нарушения мозгового кровообращения |
-
2018
- 2018-02-06 RU RU2018104548A patent/RU2694527C1/ru active
- 2018-07-10 HR HRP20231177TT patent/HRP20231177T1/hr unknown
- 2018-07-10 DK DK18182706.4T patent/DK3520786T3/da active
- 2018-07-10 PT PT181827064T patent/PT3520786T/pt unknown
- 2018-07-10 RS RS20230872A patent/RS64638B1/sr unknown
- 2018-07-10 SI SI201830994T patent/SI3520786T1/sl unknown
- 2018-07-10 LT LTEP18182706.4T patent/LT3520786T/lt unknown
- 2018-07-10 FI FIEP18182706.4T patent/FI3520786T3/fi active
- 2018-07-10 PL PL18182706.4T patent/PL3520786T3/pl unknown
- 2018-07-10 HU HUE18182706A patent/HUE062944T2/hu unknown
- 2018-07-10 ES ES18182706T patent/ES2957268T3/es active Active
- 2018-07-10 EP EP18182706.4A patent/EP3520786B1/en active Active
- 2018-08-31 US US16/119,430 patent/US11116768B2/en active Active
-
2021
- 2021-08-25 US US17/411,091 patent/US20210379059A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| LT3520786T (lt) | 2023-10-10 |
| US20210379059A1 (en) | 2021-12-09 |
| HUE062944T2 (hu) | 2024-01-28 |
| US20190240218A1 (en) | 2019-08-08 |
| PT3520786T (pt) | 2023-09-13 |
| EP3520786B1 (en) | 2023-08-09 |
| ES2957268T3 (es) | 2024-01-16 |
| US11116768B2 (en) | 2021-09-14 |
| RS64638B1 (sr) | 2023-10-31 |
| RU2694527C1 (ru) | 2019-07-16 |
| HRP20231177T1 (hr) | 2024-01-05 |
| EP3520786A1 (en) | 2019-08-07 |
| PL3520786T3 (pl) | 2024-02-12 |
| FI3520786T3 (fi) | 2023-09-05 |
| SI3520786T1 (sl) | 2023-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3520786T3 (da) | Kombination af stoffer til anvendelse i regenerativ terapi til patienter med type 1 diabetes mellitus | |
| CL2015002941A1 (es) | Usos terapéuticos de empaglifozina | |
| CL2014000801A1 (es) | Variante de factor 21 de crecimiento de fibroblasto humano (fgf21); composicion farmaceutica que lo comprende; y su uso para tratar diabetes tipo 2, obesidad, dislipidemia, sindrome metabolico o cualquier combinacion de los mismos. | |
| CL2008001612A1 (es) | 5-(3-hidroxi-7-sustituido-naftalen-2-il)-1, 1-dioxo-[1,2,5]tiadiazolidin-3-ona; su uso para tratar un trastorno hiperproliferativo; la composicion farmaceutica que los contiene; y sus procesos de preparacion. | |
| CL2012003026A1 (es) | Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad. | |
| CL2014001792A1 (es) | Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades. | |
| DK3526207T3 (da) | Heterocykliske forbindelser med aktivitet som modulatorer af muscarine m1- og/eller m4-receptorer i behandling af cns-sygdomme og smerter | |
| CL2013002053A1 (es) | Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct | |
| CL2015002835A1 (es) | Nuevos derivados de piridina | |
| BR112013029256A2 (pt) | "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina". | |
| DK2945642T3 (da) | Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme | |
| DK4005570T3 (da) | Pridopidin til anvendelse behandling af retts syndroe | |
| CL2016000026A1 (es) | Nuevos derivados de azabencimidazol | |
| IL240949B (en) | Aqueous pharmaceutical formulation for use in the treatment of type 1 or type 2 juvenile diabetes | |
| CL2013001250A1 (es) | Composicion intravenosa que contiene ibuprofeno y paracetamol combinados en dosis definidas; y uso en el tratamiento del dolor y/o inflamacion. | |
| CL2017001843A1 (es) | Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2. | |
| CL2013002971A1 (es) | Compuestos derivados de 5-(fenil/piridinil-etinil)-2-piridina/2-pirimidina-carboxamida, moduladores mglur5; composición farmacéutica que los comprende; proceso de preparación de ellos; y su uso en el tratamiento de esquizofrenia o enfermedades cognitivas. | |
| CL2017002293A1 (es) | Tratamiento de pacientes con diabetes mellitus de tipo 2 | |
| DK3843759T5 (da) | Anvendelse af tumorinfiltrerende lymfocytter til behandling af patienter med nsclc, der er refraktære over for anti-pd-1-antistof | |
| DK3558330T3 (da) | Anvendelse af mælkesyrebakterier til behandling eller forebyggelse af gestionel diabetes mellitus | |
| DK3949971T3 (da) | Anvendelse af luteolin-7-O-glucosid eller luteolin-7-O-glucuronid til fremstilling af medicin til øjenskader | |
| MA50358A (fr) | Sémaglutide en thérapie médicale | |
| CL2017002326A1 (es) | Tratamiento de pacientes con diabetes mellitus tipo 2 | |
| DK3580549T3 (da) | Ledsagende diagnostisk fremgangsmåde til anvendelse i behandlingen af cystisk fibrose med alginatoligomerer | |
| EP3930706C0 (en) | USE OF SOTAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 1 DIABETES MELLITUS |